匯創控股(08202.HK)接聯交所通知開始取消公司上市地位
匯創控股(08202.HK)公布,公司接獲聯交所日期為今年7月26日之函件,該函件乃根據創業板上市規則給予之通知,聯交所決定根據創業板上市規則暫停買賣股份,並開始取消公司上市地位。
根據該函件,公司須於該函件日期起計12個月期間,即明年7月25日提交補救建議,以證明其重新遵守創業板上市規則規定。倘若公司未能於上述限期前提交可行的建議,聯交所將會著手取消公司之上市地位。
公司指,可能於今年8月6日或之前要求創業板上市委員會覆核該決定。倘若公司並無於該日之前作出任何覆核申請,股份將自今年8月7日起暫停買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.